Volition is a multinational epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases, including some cancers and diseases associated with NETosis such as sepsis and COVID-19. In this video, we hear from Cameron Reynolds, president and chief executive officer of Volition, Dr Tom Butera, chief executive officer of Volition Veterinary, Gael Forterre, chief commercial officer of Volition, and Dr Heather Wilson-Robles, chief medical officer of Volition Veterinary, who discuss signing a global supply agreement with a market leader in pet healthcare (‘the company’). Through the agreement, the company is engaged as a worldwide provider of the Nu.Q Vet Cancer Test through its reference laboratory network for cancer indications in animal health.
Comments